“…Benign biliary diseases: Minor uses of CA 19-9 have been suggested in diseases like choledocholithiasis. A study by Gu et al [ 96 ] involving 135 patients proposed using serum CA 19-9 levels to preempt the risk of developing acute cholangitis secondary to choledocholithiasis early before disease progression[ 96 ]. This is significant as there are currently few reliable diagnostic indices for acute cholangitis in the early stages[ 96 ].…”